Skip to content
cardio.webdr
ToolsSpecialtiesEchoHeart sounds
ToolsSpecialtiesEchoHeart soundsFavoritesPrivate notes
cardio.webdr

Clinical clarity, in seconds. Built for focused decisions—not data collection.

Patient inputs stay on this device.
ExploreAll toolsSpecialtiesEchocardiographyHeart sounds
Your workspaceFavoritesPrivate notesCalculation historyOffline access
PlatformAboutFAQDevelopersFeedbackContact
© 2026 CardioWebdr Clinical support, not a substitute for judgment.PrivacyTermsStorageSupportReport an issue
All tools/Cardiometabolic & Endocrine Scores
Interactive worksheet16 clinical inputsPatient data not stored

Metabolic Syndrome (ATP III) Score Composite

: Explanation and Clinical Context The ATP III definition operationalizes metabolic syndrome (MetS) as a cluster of five components—central obesity, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting plasma glucose—of which any three confer a diagnosis. The original ATP III report (2001) used fasting plasma glucose ≥110 mg/dL; in 2005, an AHA/NHLBI scientific statement alig

Interactive worksheet

Clinical inputs

0/16 filled
On drug treatment for elevated TG
On treatment for low HDL
On antihypertensive medication
On drug treatment for elevated glucose / diabetes
Inputs stay on this device
Active structured worksheetActive local worksheet for structured input capture, review, copying, and export on this device. It deliberately makes no numerical or evidence claim without a reproducible primary source.
Clinical contextWhy this tool matters and how to interpret it

Understand the result,
not just the number.

Metabolic Syndrome (ATP III) Score Composite: Explanation and Clinical Context The ATP III definition operationalizes metabolic syndrome (MetS) as a cluster of five components—central obesity, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting plasma glucose—of which any three confer a diagnosis. The original ATP III report (2001) used fasting plasma glucose ≥110 mg/dL; in 2005, an AHA/NHLBI scientific statement aligned with ADA guidance and lowered the threshold to ≥100 mg/dL. This calculator lets you choose either the original 2001 ATP III (for historical fidelity and comparison with legacy datasets) or the 2005 update (for contemporary clinical practice).

Waist thresholds (male >102 cm; female >88 cm), triglycerides (≥150 mg/dL or on therapy), HDL (<40 mg/dL in men; <50 mg/dL in women, or on therapy), and blood pressure (≥130/85 mmHg or on antihypertensive therapy) follow ATP III/AHA-NHLBI. Ethnic-specific waist cut-points (e.g., IDF 2005) are not applied here by design; if your population warrants it, consider an IDF/harmonized variant that requires central obesity by ethnic cut-offs plus two additional criteria or uses harmonized thresholds with ethnicity-specific waists. Clinical Significance Meeting MetS criteria signals substantially increased long-term risk of atherosclerotic cardiovascular disease and type 2 diabetes.

The count of positive components (0–5) is informative: each additional positive component is associated with higher cardiometabolic risk. Management emphasizes lifestyle modification (weight reduction, diet quality, physical activity) and condition-specific pharmacotherapy (antihypertensives, statins, triglyceride-lowering agents, and glycemic management) as indicated. Clinical Interpretation Summary This tool returns a component-by-component table, a 0–5 composite count, and a diagnostic statement (≥3 components present).

Choose the 2001 or 2005 glucose threshold to match your analytic or clinical context. For Asian and other populations where lower waist cut-points are recommended, an IDF/harmonized calculator may be preferable. References National Cholesterol Education Program (NCEP) ATP III.

Executive summary and quick reference (2001). Grundy SM, et al. AHA/NHLBI Scientific Statement on Metabolic Syndrome (2005).

International Diabetes Federation (IDF) Worldwide Definition of the Metabolic Syndrome (2005) and subsequent harmonization statements (2009).

Clinical discussionModerated, tool-specific conversation

Loading discussion…

Moderated before publishingNever include patient identifiers.

Workspace mode

Structured worksheet

Active local worksheet for structured input capture, review, copying, and export on this device. It deliberately makes no numerical or evidence claim without a reproducible primary source.

On this pageWorksheet Clinical context Discussion

Privacy by default

Inputs, results, favorites, and notes remain in your browser unless you explicitly export them.

Privacy details
Report formula or content issue
Continue exploring

Related clinical tools

More in this specialty
Reference

Simon Broome Criteria Familial Hypercholesterolemia FH Calculator

General
Reference

Sex Hormone Cardiac Risk Interaction Index

General
Interactive worksheet

Lipoprotein(a) Risk Multiplier Model Calculator

Cardiometabolic & Endocrine Scores
Reference

GLP 1 RA Cardiovascular Benefit Index Calculator

General
This active worksheet captures and exports structured inputs locally. It does not assert a numerical formula or evidence claim without a reproducible primary source.